Background:Individuals with serious mental disease, especially schizophrenia, have higher rates of morbidity and mortality when compared to the overall population. The present study was conducted to assess drug-emergent metabolic syndrome in psychiatric patients receiving second-generation antipsychotics. Materials & Methods:100 patients suffering from schizophrenia were divided into three subgroups, i.e. subgroup I, subgroup II, and subgroup II, who were prescribed risperidone, olanzapine, and clozapine respectively. Group IV was a control group who were prescribed haloperidol. Measurements of blood pressure, fasting blood glucose, fasting HDL levels, fasting triglycerides level, and waist circumference were performed after 1 month and 4 months, respectively. Results: Out of 100 patients, males were 56 and females were 44. Metabolic syndrome was seen in 4 in group I, 8 in group II, 5 in group III and 0 in group IV. The difference was significant (P< 0.05). The meanFBG (mg/dl) was 80.2, 82.5, 79.2 and 78.4 in group I, II, III and IV respectively. The mean fasting TG was 82.3, 90.4, 83.2, and 77.4 in group I, II, III and IV respectively. The mean fasting HDL was 50.4, 48.2, 47.6, and 48.1 in group I, II, III and IV respectively. The mean WC was 77.6, 78.2, 79.4, and 78.0 in group I, II, III and IV respectively. The mean HC was 82.5, 84.2, 85.1, and 84.2 in group I, II, III and IV respectively. The difference was significant (P< 0.05). Conclusion: The metabolic parameters are markedly altered by second-generation antipsychotics, raising the risk of metabolic syndrome and related conditions such as type II diabetes and cerebrovascular accidents. The antipsychotic medication with the highest propensity to induce metabolic syndrome is olanzapine.